Previous close | 178.66 |
Open | 180.61 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 179.20 - 180.77 |
52-week range | 151.02 - 232.26 |
Volume | |
Avg. volume | 982,995 |
Market cap | 27.943B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | 76.05 |
EPS (TTM) | 2.36 |
Earnings date | 30 May 2023 - 05 Jun 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 210.07 |
If you've learned little in your life about the stock market -- which is likely, as financial matters are not always taught in school -- you may be assuming that you need to be at least somewhat wealthy in order to invest in the stock market. Veeva Systems (NYSE: VEEV), with a recent market value topping $27 billion, specializes in cloud-based software that helps companies in various industries -- most notably the life sciences -- operate more efficiently. For example, it helps the pharmaceutical industry manage clinical trials and get them to market faster, when possible.
Let's consider one such stock: Veeva Systems (NYSE: VEEV). Life sciences companies routinely test brand-new and unproven clinical products or technologies on patients. Veeva Systems offers a range of cloud-based software services, ranging from data storage to clinical trial management, to help life sciences companies remain legally compliant while bringing their products to market faster and more efficiently.
Salesforce (NYSE: CRM) and Veeva Systems (NYSE: VEEV) represent two very different ways to invest in the cloud-based customer relationship management (CRM) market. Salesforce, the largest cloud-based CRM company in the world, provides its services to a wide range of industries. Veeva, which was founded by Salesforce's former senior VP of technology Peter Gassner, only provides CRM services to life science companies.